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Abstract: The FOXFIRE (5-Fluorouracil, OXaliplatin and Folinic acid ± Interventional Radio-Embolisation)
clinical trial combined systemic chemotherapy (OxMdG: Oxaliplatin, 5-fluorouracil and folic acid)
with Selective Internal Radiation Therapy (SIRT or radio-embolisation) using yttrium-90 resin
microspheres in the first-line management for liver-dominant metastatic colorectal cancer (CRC).
We report clinical outcomes for patients having hepatic resection after this novel combination
therapy and an exploratory analysis of histopathology. Multi-Disciplinary Teams deemed all patients
inoperable before trial registration and reassessed them during protocol therapy. Proportions were
compared using Chi-squared tests and survival using Cox models. FOXFIRE randomised 182
participants to chemotherapy alone and 182 to chemotherapy with SIRT. There was no statistically
significant difference in the resection rate between groups: Chemotherapy alone was 18%, (n = 33);
SIRT combination was 21% (n= 38) (p= 0.508). There was no statistically significant difference between
groups in the rate of liver surgery, nor in survival from time of resection (hazard ratio (HR) = 1.55;
95% confidence interval (CI) = 0.83–2.89). In the subgroup studied for histopathology, microsphere
density was highest at the tumour periphery. Patients treated with SIRT plus chemotherapy displayed
lower values of viable tumour in comparison to those treated with chemotherapy alone (p < 0.05).
This study promotes the feasibility of hepatic resection following SIRT. Resin microspheres appear to
preferentially distribute at the tumour periphery and may enhance tumour regression.
Keywords: hepatectomy; trans-arterial radio-embolisation; brachytherapy; interventional oncology
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1. Introduction
Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States
and Europe. The liver is the commonest site for metastases from CRC and the leading cause of
patient mortality. Of the 60–70% of patients who develop colorectal liver metastases (CRCLM), half of
these will have a liver-only disease, but most of these patients will be inoperable, due to number or
distribution of metastases [1]. Hepatic resection is offered to patients with operable disease as complete
surgical resection remains the sole curative treatment for disease confined to the liver, offering the best
chance of survival [2].
Preoperative chemotherapy can be used to convert unresectable CRCLM to potentially resectable
disease [3]. The use of triplet drug regimens and biological therapies has increased radiological response
rates and complete marginal (R0) resections, in previously unresectable disease [4,5]. Despite this
progress, surgery is only feasible in up to 20% of patients with CRCLM [6,7]. Selective internal
radiotherapy (SIRT) with yttrium-90 (Y-90) microspheres is a liver-directed therapy that could
potentially improve resection rates by targeting intrahepatic liver lesions in combination with
systemic chemotherapy. SIRT exploits the arterialisation of liver metastases to deliver a high
tumour-selective dose of intrahepatic radiation. We previously showed in 20 patients that the
combination of oxaliplatin-based chemotherapy with SIRT results in high radiological response rates,
and two patients were down-sized to subsequent hepatic resection [8]. However, SIRT-related hepatic
toxicity has also been described in patients with CRCLM, so the safety of SIRT in the preoperative
setting should be established in order to consider this down-sizing combination therapy [9].
The FOXFIRE (5-Fluorouracil, OXaliplatin and Folinic acid ± Interventional Radio-Embolisation)
trial tested the hypothesis that combining systemic radio-sensitising chemotherapy (OxMdG:
Oxaliplatin, 5-fluorouracil and folic acid) with SIRT (radio-embolisation) using Y90-resin microspheres
(SIR-Spheres®; Sirtex Medical Limited, North Sydney, Australia) as a first-line treatment for liver-only
or liver-dominant metastatic CRC will improve clinical outcomes compared to OxMdG chemotherapy
alone. Although the combination treatment failed to improve overall survival, it did improve time to
progression in the liver [10]. In this report, we examine whether the combination treatment altered
clinical outcomes following liver surgery. We also developed a novel method for assessing the
distribution of microspheres in resected tissues from those patients who provided voluntary consent
(Figure 1), and we analysed the likelihood of histopathological regression in that subgroup of patients.
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Figure 1. Example of zonal analysis on histopathology. (A) Method that was developed for 
calculation of microsphere deposition density. 1 and 2 = non-neoplastic tissue (NNT), 3 = 
Tumour centre, 4 = 1–2 mm zone within tumour border, 5 = 0–1 mm zone within tumour 
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border. Slide magnification = 0.3×. (B) Illustration of the 1 mm and 2 mm zones from the 
Figure 1. Example of zonal analysis on hi t pathology. (A) Method that was developed for calculation of
microsphere deposition density. 1 and 2 = non-neoplastic tissue (NNT), 3 = Tumour centre, 4 = 1–2 mm
zone within tumour border, 5 = 0–1 mm zone within tumour border, 6 = 0–1 mm zone away from
tumour border, 7 = 1–2 mm zone away from tumour border. Slide magnification = 0.3×. (B) Illustration
of the 1 mm and 2 mm zones from the tumour margin that microsphere densities were measured within.
The highest density was found within 1 mm from the tumour periphery.
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2. Results
2.1. Patient Characteristics
A total of 364 patients were randomised in the FOXFIRE study from 13 November 2009 to 31
October 2014 across 28 centres in the UK: One hundred and eight-two to the chemotherapy alone
group, and one hundred and eighty-two to the chemotherapy with SIRT group. There were 67%
(n = 122) liver-only vs. 33% (n = 60) liver-dominant metastatic patients in the chemotherapy alone and
66% (n = 121) liver-only vs. 34% (n = 61) metastatic patients in the chemotherapy plus SIRT group.
The degree of liver involvement was ≤25% in 63% (n = 114) vs. >25% in 37% (n = 68) patients in the
chemotherapy alone and ≤25% in 63% (n = 115) vs. >25% in 37% (n = 67) patients in the chemotherapy
plus SIRT group. Full patient characteristics have been reported previously [10].
Of the 364 patients, 71 (20%) went on to hepatic resection following first-line treatment with
chemotherapy alone or chemotherapy with SIRT. In the chemotherapy alone group, 45% (n = 15)
received a biological agent concomitantly with chemotherapy (eight received bevacizumab and
seven received cetuximab. In the chemotherapy plus SIRT group, 16% (n = 6) received a biological
agent concomitantly with chemotherapy (four received bevacizumab and two received cetuximab).
Median follow-up over the course of the trial among the 71 patients who underwent hepatic resection
was 42.7 months.
Forty-seven (66%) male patients and 24 (34%) female patients proceeded to surgery (n = 71).
The study flow chart is shown in Figure 2. Twelve patients (17%) were known to have extrahepatic
disease. Measuring volume of the tumour relative to the liver, 15 patients (21%) had greater than
25% involvement of the liver by the tumour, and 56 patients (79%) had 25% or less involvement.
Demographics are shown in Table 1.
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Table 1. Demographics of the study participants who had hepatic resection during the FOXFIRE
clinical trial.
Characteristic at Baseline 1
OxMdG OxMdG + SIRT Total
(n = 33) (n = 38) (n = 71)
Age at randomisation (years) 62 (42–78) 61 (30–83) 61 (30–83)
Extra-hepatic metastases status No 28 (85%) 31 (82%) 59 (83%)
Yes 5 (15%) 7 (18%) 12 (17%)
Degree of liver involvement ≤25% 27 (82%) 29 (76%) 56 (79%)
>25% 6 (18%) 9 (24%) 15 (21%)
Gender
Male 22 (67%) 25 (66%) 47 (66%)
Female 11 (33%) 13 (34%) 24 (34%)
Ethnicity
White or Caucasian 32 (97%) 33 (89%) 65 (93%)
Asian 0 (0%) 2 (5%) 2 (3%)
Black or African American 0 (0%) 1 (3%) 1 (1%)
Other 1 (3%) 1 (3%) 2 (3%)
BMI (kg/m2)
≤30 23 (70%) 33 (87%) 56 (79%)
>30 10 (30%) 5 (13%) 15 (21%)
WHO performance status 0 29 (88%) 24 (65%) 53 (76%)
1 4 (12%) 13 (35%) 17 (24%)
Metastases present at initial diagnosis No-Metachronous 8 (24%) 5 (14%) 13 (19%)
Yes-Synchronous 25 (76%) 32 (86%) 57 (81%)
Primary tumour site Left-sided primary 25 (86%) 31 (82%) 56 (84%)
Right-sided primary 4 (14%) 7 (18%) 11 (16%)
Primary tumour in situ No 14 (42%) 16 (42%) 30 (42%)
Yes 19 (58%) 22 (58%) 41 (58%)
KRAS
Unknown 12 (36%) 10 (26%) 22 (31%)
Wild Type 15 (45%) 23 (61%) 38 (54%)
Mutation 6 (18%) 5 (13%) 11 (15%)
Prior adjuvant chemotherapy No 31 (94%) 37 (97%) 68 (96%)
Yes 2 (6%) 1 (3%) 3 (4%)
Prior pelvic radiotherapy No 32 (97%) 36 (95%) 68 (96%)
Yes 1 (3%) 2 (5%) 3 (4%)
1 n (%) for categorical variables; median (min–max) for continuous variables. OxMdG: Oxaliplatin, 5-fluorouracil
and folic acid; BMI: body mass index; WHO: World Health Organisation performance status; KRAS: Kirsten-RAS
gene status.
2.2. Surgical Details
There were 82 surgical episodes among the 71 resected patients; nine patients had two operations,
and one patient had three (Table 2). Liver surgery was performed at 16 sites, with three hospitals
performing the majority of all the operations. The liver surgery performed during the FOXFIRE clinical
trial was described using the Brisbane 2000 classification [11]. Overall, the proportion of FOXFIRE
patients to proceed to surgery in the chemotherapy alone group (18%, n = 33) and the SIRT combination
group (21%, n = 38) was not statistically significantly different (p = 0.508).
Of the total surgical episodes, four were open-and-closed and did not proceed to resection.
The commonest surgical procedures performed were right hepatectomy (n = 22), segmentectomies
(n = 12) and left hepatectomy (n = 9) (Table 2). Of the 15 patients who had >25% liver involvement,
four had a two-stage resection. Twenty-six patients had complications reported after hepatic resections,
the majority grade I and II complications (Table 3). Four patients had grade III complications
requiring surgical or radiological intervention. This included one patient who had a pneumothorax;
on resection of part of the diaphragm, microspheres were present. One post-hepatectomy liver
failure was documented. Two other patients in the combination treatment arm had reported severe
complications: Grade IVa endocarditis five months after SIRT and grade IVb pulmonary embolus,
myocardial infarction and sepsis 11.5 months after SIRT. The patient with endocarditis had a prolonged
admission of 52 days; the patient with multi-organ problems was in hospital for 15 days.
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Table 2. Classification of liver surgery performed during the FOXFIRE clinical trial. Surgical classification based on the Brisbane 2000 classification [12].
Type of Surgery Performed
Number of Surgical
Episodes (Proportion of
Total 82 Surgical Episodes)
Number of Surgical
Episodes in Chemotherapy
Alone Group
Number of Surgical
Episodes in SIRT +
Chemotherapy Group
Additional Procedures/Surgical
Comments
Right hepatectomy 22 (27%) 9 13 Two patients had subsegmentectomies(segments IVa, V; II, III)
Left hepatectomy 9 (11%) 7 2
One patient had resection of inferior vena
cava; One patient had
subsegmentectomies (ns)
Segmentectomies 12 (15%) 7 5
Segmentectomies: Two patients: II, III;
One patient each: III, VI, VII; III, IV, VII;
IVb, V, VI; IV, V, VI (and
subsegmentectomy and ablation); I, II, III;
IV and ablation; IVa, VIII. One patient
each with one segmentectomy: Vi; IV; II
(subsegmentectomy III).
Extended right
hemihepatectomy 7 (9%) 3 4 Three with subsegmentectomies (I; III; ns)
Extended left hemihepatectomy 1 (1%) 0 1
Left lateral hepatectomy 2 (2%) 0 2 Atypical
Subsegmentectomies 9 (11%) 5 4
Three patients: ns. Two patients:
Segment II only. One patient each: III;
IVa, IVb, II; V, VI, VII (ablation II, IV)
No hepatic surgery report
available 14 (17%) 5 9 Cholecystectomy in some cases
Open and closed 4 (5%) 2 2
Other 2 (2%) 1 1 First part ALPPS. Right postsectionectomy (VI, VII).
Abbreviations used: Ns: Not specified; ALPPS: Associated liver partition and portal vein ligation for staged hepatectomy.
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Table 3. Grading of surgical complications recorded in the FOXFIRE clinical trial. The table shows the
grade for all patients who had complications post-hepatic resection using a classification developed
for this indication [13]. Comparison of grades of complications between groups by Fisher’s exact test
shows no significant difference between treatment groups (p = 0.380).
Grade Number of Patients inChemotherapy Alone Group
Number of Patients in
Chemotherapy Plus SIRT Group
I 4 5
II 7 4
III 1 3
IVa 0 1
IVb 0 1
V 0 0
2.3. Time-to-Event Analyses
The median time from randomisation to hepatic resection in the chemotherapy alone arm was 7.8
months (95% confidence interval CI = 6.5–8.5) and in the chemotherapy + SIRT arm was 8.3 months
(95% CI = 7.4–9.9). There was no statistically significant difference between the time-to-resection
functions for the two treatment groups (log-rank p = 0.810) (Figure 3A). There was no statistically
significant difference in the rate of trial participants undergoing a hepatic resection between the
treatment groups (HR = 0.94; 95% CI = 0.58–1.53).
In total, 59% (42/71) of participants who had a resection had subsequently died from any
cause—52% (17/33) in the chemotherapy alone group, and 66% (25/38) in the chemotherapy + SIRT
group. Median time from resection to death in the chemotherapy alone group was 25.2 months (95% CI
= 21.0-not estimated) and in the chemotherapy plus SIRT group was 21.9 months (95% CI = 19.0–35.7).
There was no statistically significant difference in the survival functions between the treatment groups
(log-rank p = 0.164). There was no statistically significant difference in overall survival among those
resected between treatment groups (HR = 1.55; 95% CI = 0.83–2.89) (Figure 3B).
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of time from randomisation to hepatic resection for each treat t r ring the FOXFIRE study
duration. (B) Kaplan-Meier curve of time from hepatic resection to death for each treatment group
during the FOXFIRE study duration.
2.4. Histopathology Findings
Only patients who signed the voluntary consent for the use of tissue for research purposes could be
analysed in the exploratory analysis of histopathology. This equated to 27 out of 71 resected cases being
studied. In patients who were treated with chemotherapy plus SIRT, microspheres were present in all
samples. Microspheres were typically clustered around s all vessels within the tumour vasculature
and associated with macrophages (Figure S1). Using a novel method, we developed, the distribution
of microspheres was measured in microsphere/mm2 in 0–1 mm, 1–2 mm zones within and outside
he tumour margin (Figure 1). The highest density f mic ospheres was found at the 0–1 mm zones,
either side of he tumour border followed by the tumour centre (>2 mm into the tumour). The lowest
microsphere density was measured in the non-neoplastic liver tissue away from the tum ur (Table S1).
In ur analysis, there was a s atistically significant difference (p = 0.034) in the perc ntage o viable
tumour between patients treated wit SIRT (median = 0%, range 0–80%, n = 11) a d those treated with
chemotherapy alone (median = 50%, 0–85%, n = 11) (Table S2).
In the patients treated with chemotherapy plus SIRT, a macrophage, foreign body-type giant cell
reaction was observed in relation to the majority of the microspheres, confirmed by CD68 staining
(Figure 4). This took the form of individual cells and groups of cells. Inflammation and macrophage
infiltration demonstrated a non-significant trend to be higher in the chemotherapy plus SIRT group
than the chemotherapy alone group (Table S2). Smooth muscle actin staining to identify small arteries
and CD31 staining to identify endothelial cells confirmed that microspheres were not located in
small arteries, and very few were in vascular-lined spaces. The presence of microspheres outside
the endothelium suggested possible endothelial damage followed by extravasation of microspheres.
The vascular changes of sinusoidal obstruction syndrome (SOS) were seen in all cases, as previously
described in relation to chemotherapy. Two SIRT cases displayed evidence of severe vascular changes
(Figure 4). No severe vascular change was seen in those treated with chemotherapy alone. Sirius red
staining identified areas of fibrosis (Figure 4). Tumour fibrosis was more prevalent in the SIRT plus
chemotherapy group than the chemotherapy alone group (median 50% vs 10% (p = 0.018)). Both arms
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had cases of fatty infiltration, and there was no significant difference between the groups (Table S2).
In the seven cases in which microspheres were identified in the gall bladder wall, there was no evidence
of pathological changes related to these.
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3. Discussion 
This is the first detailed report of a large series of patients treated with SIRT who have undergone 
hepatic resection in a prospective clinical trial. The results demonstrate the feasibility and clinical 
outcomes of patients proceeding to surgery after chemotherapy plus SIRT. Interestingly, in a 
subgroup of the patients proceeding to surgery, we also show that the distribution of microspheres 
in resected tissue is consistent with the pathological regression of the metastases being treated. 
The aims of this surgical series were to describe the hepatic resection rate, the type of surgery 
and complications following chemotherapy or the combination of SIRT and chemotherapy. The 
results from the surgical outcomes and histological evaluation of patients receiving hepatic resection 
from both arms of the FOXFIRE trial have demonstrated the rate of surgical complications and safety 
following the addition of SIRT is comparable to chemotherapy alone. The SIRFLOX study, with the 
same trial design as the FOXFIRE study, also reported no significant difference in conversion rates to 
surgery in the patients receiving chemotherapy alone and those randomised to receive chemotherapy 
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3. Discussion
This is the first detailed report of a large series of patients treated with SIRT who have undergone
hepatic resection in a prospective clinical trial. The results demonstrate the feasibility and clinical
outcomes of patients proceeding to surgery after chemotherapy plus SIRT. Interestingly, in a subgroup
of the patients proceeding to surgery, we also show that the distribution of microspheres in resected
tissue is consistent with the pathological regression of the metastases being treated.
The aims of this surgical series were to describe the hepatic resection rate, the type of surgery and
complications following chemotherapy or the combination of SIRT and chemotherapy. The results
from the surgical outcomes and histological evaluation of patients receiving hepatic resection from
both arms of the FOXFIRE trial have demonstrated the rate of surgical complications and safety
following the addition of SIRT is comparable to chemotherapy alone. The SIRFLOX study, with the
same trial design as the FOXFIRE study, also reported no significant difference in conversion rates to
surgery in the patients receiving chemotherapy alone and those randomised to receive chemotherapy
plus SIRT—13.7% (36 patients) compared with 14.2% (38 patients) (p = 0.857) [14]. Although the
numbers of resected patients are comparable to this study, the SIRFLOX investigators did not provide
detailed information on surgical safety/complications, nor an analysis of histopathology. Reassuringly,
the incidence of complications after surgery, including a very low incidence of post-hepatectomy liver
failure, confirms the findings of a retrospective series by other investigators suggesting that surgery
is safe after chemotherapy plus SIRT for CRCLM [12]. The P4S study retrospectively analysed the
safety of hepatic resection or liver transplantation in 100 patients with various primary or secondary
liver cancers following treatment with SIRT. It concluded that the mortality, complication and liver
failure rates were similar in these patients to rates expected in patients who had not received SIRT
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prior to resection or transplantation. Similarly, a systematic review of the published literature found a
conversion rate to hepatectomy of 13.6% in 120 patients and low surgical mortality [15]. Collectively,
these studies are very relevant to multi-disciplinary teams considering SIRT to downstage tumours to
subsequent resection.
Chemotherapy-induced changes in a normal liver have been well described previously,
including steatohepatitis and sinusoidal obstruction syndrome [16–19] (Table S3). In one study
of neoadjuvant oxaliplatin-based-chemotherapy in patients with CRCLM, 44 out of 87 patients (51%)
had sinusoidal dilatation and haemorrhage, with disruption of the sinusoidal barrier compared
to none without prior chemotherapy [20]. Nearly half of these patients developed perisinusoidal
and veno-occlusive fibrosis. Vascular complications from chemotherapy alone have been described
previously: Sinusoidal vasodilatation and congestion, peliosis, haemorrhagic centrilobular necrosis
(HCN) and regenerative nodular hyperplasia (RNH) [19].
There are limited published data on histopathological changes in specimens from hepatic resections
post-SIRT (Table S4). The histology from a small number of studies has described features following
SIRT, including microsphere distribution, tumour response and changes to background liver. In one
paper, significant histological features were described [21]. Macrophages associated with a giant cell
reaction and radiation changes were described, and the absence of a cellular inflammatory response
supported the theory that SIRT caused direct radiation injury to cancer cells [21]. Our study reported
here demonstrates clusters of microspheres associated with aggregations of macrophages. This may
have some relevance to the mechanism by which the microspheres act on tumour tissue. Chew describes
the significant effect that microspheres have on the immune cells and the tumour microenvironment in
hepatocellular carcinoma [22]. Further work is required to decipher the effect that SIRT has on the
immune cells in the tumour microenvironment in patients with colorectal liver metastases.
Following resection, it is known that the microspheres are localised within tumour vasculature
and that the non-tumour bearing liver can show evidence of portal triaditis with portal and periportal
fibrosis. The largest published cohort to date confirmed resin microspheres within the vascular bed of
the tumour and portal fibrosis on the adjacent normal liver [23]. Although previous case reports have
described microspheres in the gall bladder, we report microspheres present in the gall bladder in seven
patients following SIRT. Fortunately, these patients did not report any significant clinical symptoms
from the presence of microspheres in the gall bladder, but our findings suggest that persistent upper
abdominal pain in patients who have received SIRT should be considered as possibly related to
radiation cholecystitis until an alternative clinical cause for the pain is found.
Due to the ethical requirement for separate voluntary consent to analyse histopathology specimens
from surgical resection, there were limited numbers of patients for detailed histological analysis.
Despite this limitation, we performed an exploratory comparison of histopathological changes in
cases treated with chemotherapy alone, versus those treated with chemotherapy plus SIRT (Table S2).
Interestingly, the SIRT cases had a lower percentage of viable tumour than those treated with
chemotherapy alone (p = 0.034), and tumour necrosis occurred at a higher rate in cases treated with
chemotherapy alone (p = 0.054). Additionally, the novel methodology we developed for the zonal
analysis of metastases demonstrated that the cases, which displayed the highest percentage of viable
tumour within the SIRT group, had the lowest microsphere densities within the cohort (Table S1).
This is preliminary evidence in favour of the hypothesis that microsphere density is inversely related
to the percentage of viable tumour post-treatment. The high microsphere density we observed at the
tumour periphery is consistent with dosimetric studies published over a decade ago [24].
This report represents the most detailed description of surgical and histopathological findings of
patients treated prospectively within a clinical trial of chemotherapy plus SIRT for CRCLM. Despite our
finding that off-target delivery of microspheres to the gall bladder is frequent, we conclude that surgery
after chemotherapy combined with SIRT is feasible. Our novel histopathological analysis provides
evidence in favour of the hypothesis that SIRT resin microspheres preferentially distribute at the
tumour periphery and that they can enhance regression of liver metastases.
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4. Materials and Methods
The FOXFIRE trial was conducted according to the principles of ISO14155, Good Clinical Practice
and the Declaration of Helsinki. Ethical approval was granted by the Berkshire Research Ethics
Committee (ethics number 09/H0505/1). The trial registration number was ISRCTN83,867,919.
4.1. Trial Participants and Treatments
Patients had to be eligible for systemic chemotherapy as first-line treatment for metastatic
CRC. Inclusion criteria included: Histologically confirmed CRC with inoperable liver-only or
liver-dominant metastases with or without the primary tumour in situ (“inoperable” agreed at
Liver Multidisciplinary Team meeting with liver surgical representation), performance status 0 or
1, age ≥ 18 years, life expectancy ≥ three months. All patients provided written informed consent.
Exclusion criteria included: Ascites, cirrhosis, portal hypertension (all determined by a clinical or
radiological assessment); thrombosis of the main portal vein. Clinical trial details, including eligibility
criteria and treatments, have previously been reported in detail [10,25].
Systemic chemotherapy consisted of OxMdG (85 mg/m2 oxaliplatin infusion over 2 h, l-folinic
acid 175 mg or d, l-folinic acid 350 mg infusion over 2 h and 400 mg/m2 bolus 5-FU followed
by a 2400 mg/m2 continuous 5-FU infusion over 46 h). Each chemotherapy cycle lasted 14 days.
Protocol chemotherapy was 12 cycles, with the provision to interrupt it for liver surgery. It was
mandated that all patients should be discussed at the Liver Multidisciplinary Team meeting with liver
surgical representation to consider liver surgery after six cycles of chemotherapy. The oxaliplatin
dose was reduced from 85 mg/m2 to 60 mg/m2 for three cycles around SIRT, based on the phase
I–II data previously published by the investigators [8]. Addition of biologically targeted drugs was
permitted as previously described [10,25]. A hepatic arteriogram and a liver-to-lung breakthrough
nuclear medicine scan were used to assess patient suitability to receive the SIRT. The patient’s body
surface area, percentage tumour involvement, and magnitude of liver-to-lung shunting were used
to determine the activity (GBq) per dosing charts [25]. Planned SIRT with Y90-resin microspheres
(SIR-Spheres®, Sydney, Australia), was with cycle 2 day 3/4, although it could be given with cycle 1 or
cycle 3 under the circumstances defined in the protocol.
4.2. Histopathology and Immunohistochemistry
In patients who gave voluntary consent to study tissue for research purposes, sections of formalin
fixed paraffin embedded tissue (liver in 27 cases, gall bladder in 18 cases) were scanned using the
Aperio AT Turbo digital scanner (Leica Microsystems, Milton Keynes, UK) and used for the assessment
of: Tumour viability and regression, fibrosis and microsphere distribution. The sections were stained
with Haematoxylin and Eosin, and Sirius Red to assess fibrosis. An assessment of vascular pathology
and fatty change away from the tumour was also performed.
The density and distribution of microspheres were determined using zonal analysis using Aperio
ImageScope (Leica Microsystems, Milton Keynes, UK). An estimation of the density of microspheres
counted manually in Non-Neoplastic Tissue (NNT) was calculated using a mean average of the density
in two 3 mm × 3 mm to 5 mm × 5 mm areas of tissue for each case (3 mm × 3 mm regions were used
in cases where limited NNT was present). A microsphere density for the tumour centre was also
counted manually; the tumour centre was defined as the area 2 mm proximal to the tumour border.
Sphere densities within the 1 mm and 2 mm zones of the tumour border and the tumour centre were
expressed as a ratio of the sphere density calculated for the NNT (Figure 1).
Immunohistochemical staining for CD68 (PGM1, Dako M087601-2), smooth muscle actin (ab12496,
ABCAM EPR5368) and CD31 (ab7817, DAKO M0823) were performed on the Leica Bond III automated
immunostaining platform using Leica Bond Polymer Refine detection with DAB chromogen (Leica
DS9800; Buffalo Grove, IL 60089, USA). Dewaxing and peroxidase blocking were performed on-board
as per kit, according to the manufacturer’s instructions. The antibody was applied for 15 min at room
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temperature, following on-board heat-induced epitope retrieval (HIER) for 30 min at 99 ◦C with Leica
Epitope Retrieval 1 solution (pH 6, Leica, AR9961).
4.3. Statistical Analysis
The hepatic resection rate was defined as the number resected in the randomised group divided by
the number randomly assigned to that group. Time-to-event analyses were performed in the subgroup
of FOXFIRE patients who underwent hepatic resection. For patients who underwent multiple hepatic
resections, the first occurrence was used in the time-to-event analyses. The time from randomisation
to resection was defined as the time (months) from randomisation to undergoing hepatic surgery.
The time from resection to death was defined as the time (months) from undergoing hepatic surgery to
death by any cause. Patients not recorded as dead following surgery were censored at their last known
alive date. Surgical complications were graded as previously published [13], and grades included any
deviation from normal post-operative course to grade 4-organ failure. A Fisher’s exact test was used
to assess the association between complication grades and the treatment group. The proportion of
patients to have undergone a hepatic resection in each group was compared using a chi-squared test.
Time-to-event between groups was compared using Kaplan-Meier curves, Cox proportional hazards
models (the proportional hazards assumption was tested using Schoenfeld residuals) and log-rank
tests. Median follow-up for the entire study period among those resected was estimated using the
reverse Kaplan-Meier method. A Mann-Whitney U test was used to compare tumour characteristics
between groups, such as the percentages of viable tumour in SIRT group vs. Chemotherapy only
group. A two-sided 5% significance level was used for all tests. Statistical analyses were performed in
STATA 15 and GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA, USA).
5. Conclusions
We report the safety of hepatic resection after the novel combination of systemic OxMdG
chemotherapy (oxaliplatin, 5-fluorouracil and folic acid) with SIRT in the first-line management
of liver-dominant metastatic colorectal cancer, compared to OxMdG chemotherapy alone, and we
present an exploratory analysis of histopathology. A Multi-Disciplinary Team deemed all patients
inoperable before registration. FOXFIRE randomised 182 participants to chemotherapy alone and
182 to chemotherapy with SIRT. There was no statistically significant difference between groups
in the rate of liver surgery, nor in survival from time of resection (HR = 1.55; 95% CI = 0.83–2.89).
Ectopic microsphere deposition in the gall bladder was an incidental histological finding. Microsphere
density was highest at the tumour periphery. Patients treated with SIRT plus chemotherapy displayed
lower values of viable tumour in comparison to those treated with chemotherapy alone (p < 0.05).
We conclude that liver surgery should be considered following the clinical response to SIRT.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/8/1155/s1,
Figure S1. (A) Low power view of liver, with microspheres taken from a digitised image (Haematoxylin and
Eosin stained section, original magnification ×20). (B) High power view of microspheres taken from the same
digitised image as the previous slide (Haematoxylin and Eosin stained section, original magnification ×400).
Table S1: Microsphere densities and distribution demonstrated on zonal analysis, Table S2: Histological findings
in tumour and non-neoplastic liver tissue in individual cases receiving chemotherapy-alone or chemotherapy plus
SIRT, Table S3: Histological effects seen in hepatic resection specimens after chemotherapy, Table S4: Histological
changes observed in hepatic resection specimens from patients having SIRT prior to resection.
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